Morepen Laboratories has developed and added three new drugs to its portfolio of Active Pharmaceutical Ingredients (APIs) for sale in domestic and global markets. The three bulk drugs / APIs are Rivaroxaban (trade name-Xarelto), Vildagliptin (trade names- Galvus, Zomelis) and UDCA (Ursodeoxycholic Acid). While two products Rivaroxaban and Yildagliptin will augment the company’s presence in the Cardiac and Diabetic segments respectively, the third product UDCA will cater to the Liver segment.
Morepen Laboratories is a well-known pharma company having well equipped Research & Development Centre and is all set to seize the Generic revolution in pharma industry, by filing multiple DMFs and COS for new APIs.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1618.50 |
| Dr. Reddys Lab | 1312.40 |
| Cipla | 1295.00 |
| Zydus Lifesciences | 930.00 |
| Lupin | 2285.05 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: